reported (or Feldene exceeds that reported to the System for benoxaprofen (Oraflex), a structurally unrelated nonsteroidal antiinflammatory agent that has been withdrawn from the market. The original package insert for Feldene does not list photosensitivity as an adverse reaction associated with its use. Yet 29 of 36 reactions asso-( iated with this drug were clinically ((insistent with photosensitivity reactions, and 2 of the remaining 7 reports of reactions were highly suggestive of exacerbation by exposure to sunlight. The 29 patients who had photosensitive eruptions (lb men and 13 women) ranged in age from 20 to 74 years; one patient (a man) was black. In 19 of the 29 patients the eruption occurred within four days and after llieii first sun exposure after the initiation of Feldene therapy. A majority of the cases included vesicles or bullae in sun-exposed Ninas. Pruritus was frequently associated with the eruption.
The prompt onset of the eruption in relation to initial treatment and sun exposure suggests a pholotoxic rather than a pholoallcrgic reai lion. I line patients who had used thiazide diuretics for extended-periods ol time experienced photosensitivity reactions after feldene was added to their therapeutic regimens, suggesting possible additive or synergistic phOtOlOxie elicits of feldene and thiazides.
Huston, MA 0221 5
Beth Israel Hospital flic above letter was referred 10 Phzei Laboratories, manufacturers ol feldene, who oiler the lollow nig reply:
I a Ike I'.dilo!: Although Dr. Stern correctly notes thai the original feldene (piroxicam) package insert did not list photosensitivity reactions, thev were added in August 1982, three months before we received a communication from him. We made this change vOiunl Miily because we had received reports of such reactions (including cases bom Dr. .Stein) alter feldene was introduced, even though we had iifil seen them in more than 1000 patients studied in our con trolled clinical trial*. We believe thai our current labeling, which stales that these read ions occur m fewer (ban 1 per cent of patient!, is supported by tins experience.
Some government agencies, such as the Cou'imittce on Safety of .Medicines m the United Kingdom and the Swedish Regulator) Authority, routinely report information on advene reactions. Data bom llnse agencies suggcW that the incidence of phOtOICtUtlivil) reactions with Feldene is probably on the same order ol magnitude as (In incidence with olhei marketed nonsteroidal antiinflammatory dings, including ibupiolni, mdomriharui, and .naproxen Ph/ri has recently reviewed side efleCti in over 70,000 patients mound the win Id wl)0 were Heated will I'rldriit\xix well as m COftl paialiw Studies with mdi anel hai in and napioxrii I >r' i mat, llogK icai lions of anv kind o'ciuicd m about I to 3 per cent ol palicnts and had a sunilai u>< idence with each ol the drugs.
Finally, it Shook) be itoted dial benoxnpijulcu was witlnbawii from iltc market because ol hepatic and rsrtal toxicity, not because ol photosensitivity, as implied ill Di Nteni't lillfi Tu III' tidiloi A icpi'M In (teller et al, presented pit'hnnn.ii \ results siiui/esinig j|ie possible iiselulness Of (enfluiamine (a subsliluted pliruv let h\ lariunr vs it Ir I \ used as all ap|»elile tinppi rssatil I m lite it i ai men I of infantile autism (July 15, I 982, issue) I lie i a ton ale ("i the use Of tljll agent rGstl on ill ability to lowei peripheial blond levels ol seioioniii and on die olnri v alion dial a <uibslanl ial iniflOriiy of^HUlillit prtx-onx have elevated peripheral hlOotl KTQ loiuii levelfC I he report emphasized the prehminaiv tiatute of the result* in a small sgiuple of three vouug aulistii bOVI With elcvaled i loioihii level* We have seen two our! m wltit li autistic t hildren writ In Iliad vx 11! i I Ins agent ,oid appealed to have advene icai lioiu to it. In neither ease was peripheral serotonin measured before treatment.
A seven-year-old boy had been diagnosed as autistic al the age of five. I he child had a variety ofj.he features typical of autistic children and was enrolled in a special-education program. His pediatrician had given him fenfluramine. 10 nig four times a day,, During one month of treatment'with this agent the child became progressively irritable and fearful. His activity level increased as his appetite decreased. Sleep was also disrupted. He deteriorated behaviorallv. and his family discontinued the medication. At our examination, performed two months after treatment had been stopped, his serotonin levels were not elevated (152 ng per milliliter)."
An 1 1-year-old autistic bov had been started on fenfluramine (10 mg four times a day) by his father, who had read the preliminary' report by Gellcr et al Serotonin levels were not determined before treatment. Over several days of treatment the child became more irritable and agitated. Fenfluramine was discontinued. The box's activity level was markedly increased during the time of treatment, and his father sought an evaluation. At oui examination, one month alter treatment had been discontinued, the child had a serotonin level of 2 I 2 ng per milliliter.
Adverse reactions to fenfluramine have been noted previously. In one double-blind investigation the elluacv of this agent as an appetite suppressant was evaluated; both patients and phvsuians were able lo identify the a< live agent Correctly in over 70 pel cent of Cases largely on the basis ol side eHect.
1
There is no rationale lot the use "I fenfluramine in autistic children who do not have elevated levels of serotonin furthermore, its efficacy m this population remains to be clearly established. Physicians should lie aware ol possible adverse effects ol this agent in autistic Children and its investigational nature ! Sun e Novernbei 1982, WC have had the uppottunil v lo lollow (lie patieul described hi then report and wish lo prov iile lollow up data thai .o gur ac.i mst I he i "!<-ol < nun icbue in inducing polymyositis in t|\is patient.
Although ci | net nil ne had been dis, oniinued m |anu.u \ I ' *H' .' ihr patient had active myositis when first seen }, >• us fo January IUH-, while taking prednisone (60 fflfi pet day) and njen aptopui me (SO ma tliife tiinex a day), he had a severe e,xacerbatii>n ol myosins ih profound weakness and elevation ol kinai .' K' l.OI Nl II pet hlei He denied uxinji i unci aluir oi ,,|i ohol Sun < iheu his myositis has irmaiueil BCttvt despite lie.ument with hitdi ,|. piednisoiir and methotrexate It is appareni thai l '< months alter diseoniinuaiiofl oi, irrn?lidinf t , this [latietu lontimiex to have progressivt polymyositis t*hl 'hatplv wnil |ue\lonsK reported eases of drug induced polv myositis, in which remission of diseast was oljuerved WK>H aAet ilisi onimiiation of the thug Kot example, in all previous)) rtSK»rted , ,oi • of peine illamnti axsoi i ft ted (Vols mvosius rerllisStl HI ot I too kl '' impiovement in hoil, ihtu.al and labm .
< lot w teBinies ol rnvositio,, in ied within six months o( stopping the drug In no cww
